Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Sibel Health Awarded a $3.5 million ARPA-H Direct-to-Phase II SBIR Contract to Develop a First-In-Class Wearable Sensor for Continuous Edema Monitoring